While bortezomib treatment or tumor growth did not change the expression of CD8+ T cell miR-31a expression, tumor growth exacerbated CD8+ T cell miR-17b and miR-34a expression, which was further enhanced by bortezomib treatment. The gene discussed is CD8A; the disease is neoplasm.